Sleep Apnea Clinical Trial
— CPAPPsOfficial title:
A Pilot Study of CPAP Adherence Promotion by Peer Buddies With Sleep Apnea
Verified date | February 2013 |
Source | VA Office of Research and Development |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
Obstructive sleep apnea (OSA) is a highly prevalent condition in veterans with some
estimates as high as 47%. Poor adherence to the primary treatment of OSA -- continuous
positive airway pressure (CPAP) therapy - is associated with increased risk for heart
attacks, strokes and even death. The investigators plan to improve CPAP adherence in
veterans through their interactions with peers who have successfully adopted CPAP therapy.
Such "peer-buddies" may promote the well-being of veterans while remaining highly
cost-effective when compared to healthcare providers. Our strategy is grounded on the
rationale that veterans as a group are ecoculturally more homogenous than expected for the
given level of differences in age, gender, ethnicity, or socioeconomic strata. Our long-term
objectives are to initiate a larger, multi-site, research study for enhancing CPAP adherence
in veterans with OSA. The ultimate goal of this research is to develop a cheap, effective
and exportable system of care to promote CPAP adherence in patients with OSA.
Status | Completed |
Enrollment | 60 |
Est. completion date | June 2012 |
Est. primary completion date | June 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 21 Years to 85 Years |
Eligibility |
Inclusion Criteria: 1. Obstructive Sleep Apnea (defined by Apnea-hypopnea index [AHI] > 5 per hour; with hypopneas defined as greater than 30% reduction in airflow with 4 or greater drop in oxygen saturation). AHI will be determined by full night or split-night polysomnography. 2. Age range 21 - 85 years old. 3. Stable medical history and no change in medications, including anti-hypertensive and thyroid replacement, in the previous 4 months. 4. No regular use (> 3 times/week) of sedative or hypnotic medications in the last 4 months. Exclusion Criteria: 1. Central sleep apnea (central apnea index > 5 per hour and >50% of Apnea-hypopnea index constituted by central apneas and non-obstructive hypopneas). 2. Complex sleep apnea or CPAP emergent central apnea (Central apnea index > 5 per hour during CPAP titration with >50% of Apnea-hypopnea index constituted by central apneas and non-obstructive hypopneas). 3. Requiring oxygen or bi-level positive airway pressure for treatment of OSA or hypoventilation. 4. Decompensated cardiac (heart failure or angina) or pulmonary (severe COPD or uncontrolled asthma) disease 5. Chronic narcotic use 6. Nasal obstruction (nasal congestion score > 15) or enlarged tonsils 7. Diagnosis of another sleep disorder in addition to OSA based on PSG (e.g., periodic limb movement disorder [ 15 limb movements/hour of sleep with arousal], central sleep apnea [ 50% of apneas on diagnostic PSG are central apneas], insomnia, obesity hypoventilation syndrome, or narcolepsy). 8. Previous treatment with positive airway pressure, home oxygen therapy, tracheotomy, uvulopalatopharyngoplasty, or other surgery for OSA. 9. Night shift workers in situations or occupations where they regularly experience jet lag, or have irregular work schedules by history over the last 6 months. 10. Routine consumption of more than 2 alcoholic beverages per day. 11. Recent or recurring history of recreational drug use leading to tolerance or dependence. 12. Unable to perform tests due to inability to communicate verbally, inability to write and read in English; less than a 5th grade reading level; visual, hearing or cognitive impairment (e.g. previous head injury); or upper extremity motor deficit (e.g., previous stroke that prevents patient from using CPAP treatment). |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Southern Arizona VA Health Care System, Tucson, AZ | Tucson | Arizona |
Lead Sponsor | Collaborator |
---|---|
VA Office of Research and Development |
United States,
Parthasarathy S. The need for pharmacovigilance in sleep medicine. Sleep. 2011 Jul 1;34(7):827-8. doi: 10.5665/SLEEP.1096. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Functional Outcomes of Sleep Questionnaire (FOSQ) | Three months | No | |
Secondary | CPAP adherence | Three months | No | |
Secondary | Patient Activation Measure (PAM) survey assessment tool | Three months | No | |
Secondary | Self efficacy measure for sleep apnea | Three months | No | |
Secondary | Psychomotor vigilance test | three months | No | |
Secondary | Patient acceptability of peer-based intervention | Three months | No | |
Secondary | Epworth sleepiness score | Three months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05582070 -
Effect on Sleep of Surgical Treatment of Severe Nasal Obstruction
|
N/A | |
Recruiting |
NCT03919955 -
A Novel Pharmacological Therapy for Obstructive Sleep Apnea
|
Phase 2 | |
Completed |
NCT03927547 -
Sleep Disordered Breathing and Cardiopulmonary Disease in Peruvian Highlanders
|
N/A | |
Recruiting |
NCT04007380 -
Psychosocial, Cognitive, and Behavioral Consequences of Sleep-disordered Breathing After SCI
|
N/A | |
Completed |
NCT02188498 -
Electrocardiography Data Analysis in Sleep Disorders
|
||
Completed |
NCT01503164 -
Effects of Continuous Positive Airway Pressure (CPAP) on Glucose Metabolism
|
N/A | |
Recruiting |
NCT00747890 -
Surgical Treatment of Mild Obstructive Sleep Apnea
|
N/A | |
Active, not recruiting |
NCT00738179 -
Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea to Prevent Cardiovascular Disease
|
Phase 3 | |
Completed |
NCT00841906 -
Alice PDx User/Validation Extended Trial
|
N/A | |
Completed |
NCT00202501 -
Usefulness of Nasal Continuous Positive Airway Pressure (CPAP) Treatment in Patients With a First Ever Stroke and Sleep Apnea Syndrome
|
N/A | |
Completed |
NCT00047463 -
Effects of Treating Obstructive Sleep Apnea in Epilepsy
|
Phase 2 | |
Not yet recruiting |
NCT06029881 -
Portable System for Non-intrusive Monitoring of Sleep
|
||
Recruiting |
NCT06093347 -
Central Apnoea Monitor Study
|
||
Terminated |
NCT05445869 -
Severe OSA Study (SOS)
|
N/A | |
Withdrawn |
NCT04096261 -
The Importance of Sleep Quality and the Blood-brain Barrier in Cognitive Disorders and Alzheimer's Disease
|
||
Recruiting |
NCT04575740 -
Phenotyping Mechanistic Pathways for Adverse Health Outcomes in Sleep Apnea
|
N/A | |
Completed |
NCT04676191 -
Validation of a Contactless Vital Signs Measurement Sensor
|
N/A | |
Recruiting |
NCT06015620 -
Comorbidities Resolution After MGB Surgery and Change in Body Composition
|
||
Completed |
NCT06051097 -
Metabolic Syndrome and Obstructive Sleep Apnea
|
||
Completed |
NCT05687097 -
Untreated Sleep Apnea as an Aggravating Factor for Other Secondary Medical Conditions After Spinal Cord Injury
|